Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|Neoplasms
Interventions: DRUG: neratinib
Sponsor: Puma Biotechnology, Inc.